Pfizer Inc. $PFE Shares Acquired by Raleigh Capital Management Inc.

Key Points

• Raleigh Capital Management Inc. increased its stake in Pfizer Inc. by 23.5% during the second quarter, acquiring an additional 14,824 shares, bringing their total to 77,832 shares worth approximately $1.887 million.
• Pfizer's stock has a current price of $23.84, positioning it between its 52-week low of $20.92 and high of $30.43, with a market capitalization of $135.54 billion.
• Equities analysts have updated price targets for Pfizer, with recommendations ranging from a neutral rating to a strong buy rating, reflecting a consensus target price of $28.12.

Raleigh Capital Management Inc. lifted its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 23.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,832 shares of the biopharmaceutical company's stock after purchasing an additional 14,824 shares during the quarter. Raleigh Capital Management Inc.'s holdings in Pfizer were worth $1,887,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Capital Advisory Group Advisory Services LLC raised its position in Pfizer by 2.9% during the second quarter. Capital Advisory Group Advisory Services LLC now owns 13,542 shares of the biopharmaceutical company's stock worth $328,000 after acquiring an additional 388 shares during the period. Trust Co of the South raised its position in Pfizer by 1.5% during the second quarter. Trust Co of the South now owns 29,386 shares of the biopharmaceutical company's stock worth $712,000 after acquiring an additional 441 shares during the period. Charter Oak Capital Management LLC raised its position in Pfizer by 4.3% during the second quarter. Charter Oak Capital Management LLC now owns 10,663 shares of the biopharmaceutical company's stock worth $258,000 after acquiring an additional 444 shares during the period. Ballentine Partners LLC raised its position in Pfizer by 0.5% during the second quarter. Ballentine Partners LLC now owns 93,228 shares of the biopharmaceutical company's stock worth $2,260,000 after acquiring an additional 458 shares during the period. Finally, Members Trust Co raised its position in Pfizer by 2.1% during the first quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company's stock worth $587,000 after acquiring an additional 467 shares during the period. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Up 0.3%

NYSE PFE opened at $23.84 on Tuesday. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The business's fifty day simple moving average is $24.54 and its 200-day simple moving average is $24.11. The firm has a market cap of $135.54 billion, a PE ratio of 12.68, a P/E/G ratio of 0.77 and a beta of 0.55.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same quarter in the previous year, the firm earned $0.60 EPS. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have weighed in on PFE shares. Citigroup upped their price objective on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Morgan Stanley raised their price objective on Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a report on Wednesday, August 6th. Bank of America raised their price objective on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a report on Wednesday, August 6th. Finally, Wall Street Zen lowered Pfizer from a "buy" rating to a "hold" rating in a report on Sunday. Two research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.